Crocetin ameliorative effect on diabetic nephropathy in rats through a decrease in transforming growth factor-β and

Mohammad Mazani1, Sina Mahdavifard2, Alireza Koohi3

  • 1Professor of the Department of Clinical Biochemistry, Ardabil University of Medical Sciences, Ardabil, Iran.

Clinical Nutrition ESPEN
|December 6, 2023
PubMed
Abstract

Insights

Crocetin (Crt) treatment improved diabetic nephropathy (DN) in rats by reducing glycation, oxidative stress, and inflammation. This natural compound also improved metabolic profiles and protected kidney tissue.

Area of Science:

  • Nephrology
  • Pharmacology
  • Biochemistry

Background:

  • Diabetic nephropathy (DN) involves glycation, oxidative stress, and inflammation, often linked to elevated transforming growth factor-β1 (TGF-β1).
  • Investigating novel therapeutic agents is crucial for managing DN progression and its associated complications.

Purpose of the Study:

  • To evaluate the therapeutic effects of crocetin (Crt) on renal histopathology, TGF-β1, and markers of glycation, oxidative stress, and inflammation in a rat model of DN.
  • To determine Crt's impact on metabolic parameters including glycemia, insulin resistance, and lipid profiles in DN rats.

Main Methods:

  • Diabetic nephropathy was induced in male Wistar rats using a combination of nephrectomy and streptozotocin.
  • Rats were divided into normal, normal + Crt, DN, and DN + Crt groups, with Crt administered intraperitoneally (100 mg/kg) monthly for 3 months.
  • Assessed parameters included renal function markers, various glycation and oxidative stress markers, inflammatory cytokines, and TGF-β1 levels.

Main Results:

  • Crocetin treatment significantly reduced biochemical and histopathological markers of renal dysfunction, including glomerulosclerosis.
  • Crt administration ameliorated diverse glycation, oxidative stress, and inflammatory markers while improving glycemia, insulin resistance, and dyslipidemia.
  • The treatment increased the activity of glyoxalase-1 (GLO-1) and paraoxonase-I (PON-1) and decreased serum TGF-β1 levels.

Conclusions:

  • Crocetin demonstrates significant protective effects against diabetic nephropathy in rats, primarily through an improved metabolic profile.
  • The compound's ability to reduce TGF-β1, oxidative stress, glycation, and inflammation, coupled with enhanced GLO-1 activity, highlights its multi-faceted renoprotective potential.